

OriCiro Genomics opens new office in North America

19 May 2022 | News

OriCiro is focused on the development and commercialization of cell-free synthesis and amplification technology of genome-scale large DNA for applications in gene/cell-based therapy and synthetic biology



Japan-based OriCiro Genomics K.K., a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, has announced the opening of US office in North America.

OriCiro has rapidly developed its cell-free cloning technology over the past two years, launching three cell-free DNA tools as reagent kits and 700 reagent kits have been sold worldwide so far.

At the same time, OriCiro has expanded custom services to accept up to 200 kb size of DNA. They have been ordered and delivered for seven projects that were failure or difficult to synthesize using PCR or cell-based cloning methods. 60% of their sales come from customer outside of Japan.

To further expand their business, OriCiro is entering North America, the largest market in the life science industry.

The US office will cover North America and Canada. They already have a sales force in place. They can accept order directly from those territories and customers in the following product and services.